Merck Not Giving Up On Arcoxia U.S. Approval - Yet
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Clark says Merck continues to believe that the Vioxx follow-on could be “a valuable treatment” option for patients.
You may also be interested in...
Arcoxia GI Benefit Does Not Outweigh CV Risk, Committee Says
FDA’s Arthritis Drugs Advisory Committee votes 20-1 against recommending approval of Merck’s Vioxx follow-on etoricoxib.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products